SCHEMBL4487564

SCHEMBL4487564

[CH]c1nc(C(=O)NCC)co1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.39
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 3/20 0.36
ITGAV P06756 1/20 0.36
HDAC6 Q9UBN7 4/20 0.36
HDAC1 Q13547 3/20 0.36
HDAC8 Q9BY41 3/20 0.36
HPGD P15428 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GAA P10253 2/20 0.35
NPC1 O15118 2/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
KLKB1 P03952 3/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC4 P56524 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162739 0.81 CNR1 (0.40) CNR1KDM4ENPSR1HSD17B10RAB9A
SCHEMBL13631423 0.81 ITGAV (0.50) CNR1KDM4ENPSR1HSD17B10ITGAV
SCHEMBL4480406 0.80 HDAC1 (0.38) CNR1RAB9AHDAC6HDAC1HDAC8
SCHEMBL4485511 0.78 HIF1A (0.46) CNR1HDAC6HDAC4
SCHEMBL4486489 0.76 NPC1 (0.46) CNR1KDM4ERAB9AHDAC6HDAC1
SCHEMBL4484701 0.73 DAGLA (0.42) KDM4ENPSR1RAB9AHDAC6HDAC1
SCHEMBL14393704 0.71 MCL1 (0.40) CNR1KDM4ENPSR1HSD17B10ITGAV
SCHEMBL4481455 0.70 RAB9A (0.48) RAB9AHPGDSMN1; SMN2GAANPC1
SCHEMBL4498214 0.69 HIF1A (0.41) CNR1KDM4ENPSR1HSD17B10RAB9A
SCHEMBL31604665 0.68 HDAC6 (0.51) HDAC6HDAC1HDAC8HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 EP disclosed
US-20060063765-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-03-23 US disclosed
EP-1487828-A2 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LIMITED (GB) 2004-12-22 EP disclosed
WO-2003082861-A2 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063765-A1 Novel compounds CCR3, NSUN3, CCR1 CNR1 112/4885KDM4E 3967/4885NPSR1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.